Procedure transmitted live from Fu Wai Hospital to over 4,000 attendees at 22ndannual TCT Asia-Pacific Cardiovascular Summit
WALTHAM, MA — APRIL 26, 2017 — Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announced today that Fu Wai Hospital in China performed and broadcast live a PCI procedure using the CorPath GRX System to more than 4,000 attendees at the 22nd annual TCT Asia-Pacific Cardiovascular Summit. The annual conference, being held in Seoul, South Korea, attracts attendees from 44 countries, with a majority of attendees from the Asia-Pacific region.
The CorPath GRX System, temporarily placed at Fu Wai Hospital for investigational use, is the first installation of the next-generation CorPath System outside of the United States. Dr. Kefei Dou, Deputy Director of Coronary Artery Disease for the Department of Cardiology at Fu Wai Hospital, successfully performed the first robotic-assisted PCI procedures in Asia in March, with this case being the second one transmitted via live feed. Fu Wai Hospital is the largest hospital in China and specializes in the treatment, prevention and research of cardiovascular diseases and hypertension and their related complications. According to Millennium Research Group, China is the second largest PCI market in the world.
"The Asia-Pacific region represents a variety of markets that are strategically important as we continue to grow our business internationally. We are encouraged by the positive feedback we have received from physicians in response to both live cases regarding the capability and potential for robotics in the region," said Tal Wenderow, Corindus Co-Founder and Executive Vice President International & Business Development.
"Having been involved in the first live case and on the panel for the second, I am impressed with the speed with which Dr. Dou and his team mastered the CorPath technology. The discussion around the precision capabilities, applicability of robotics in complex PCI, and the vision of where the technology can go has spurred tremendous interest in the interventional community," said J. Aaron Grantham, M.D., Corindus Chief Medical Officer.
CorPath GRX offers enhancements to the CorPath platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. Physicians now have independent and simultaneous robotic control of guide catheters, guidewires, and balloon/stent catheters, with one-millimeter advancement capability, from the workstation console. This precise positioning that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: